Product Description: Narlaprevir (Standard) is the analytical standard of Narlaprevir. This product is intended for research and analytical applications. Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM[1]. Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease[2]. Narlaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.3 μM[3].
Formula: C36H61N5O7S
References: [1]Ashok Arasappan, et al. Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS<sub>3</sub> Serine Protease Inhibitor. ACS Med Chem Lett. 2010 Feb 15;1(2):64-9./[2]X Tong, et al. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS<sub>3</sub> protease. Antimicrob Agents Chemother. 2010 Jun;54(6):2365-70./[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.
CAS Number: 865466-24-6
Molecular Weight: 707.96
Research Area: Infection
Target: HCV;HCV Protease;Reference Standards;SARS-CoV
Deutsch
English
